The DOI matches its Crossref record; 757 of the 757 references it cites were found in a registry or an index.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Open accessAbstract
A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of them have been produced in high- income countries and integrate scien - tific evi dence with expert opinion 42- 45 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NICE 27 , the BAP 12 , MIMS online 28 , and UpToDate 29 , suggest tapering periods of between two and four weeks, with linear reductions of dose down to minimum therapeutic doses, or half that, before complete cessation.”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to a study, most severe depression patients are still advised to consider SSRIs as the initial choice for treatment. 350”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [350]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, quetiapine (mean dose,156.74 ± 97.6 mg/day) showed significant benefits for both response and remission rates compared to placebo, which is in accordance with current clinical recommendations for augmentation strategies for MDD (Cleare et al., 2015; Kennedy et al., 2016).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Cleare et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“and of these, 4 (19%) included a specific statement on the risk of misinterpreting withdrawal symptoms as depressive relapse, stating that withdrawal symptoms may ‘mimic’, 48 ‘be misdiagnosed as’, 2 ‘mistaken for’ 28 or ‘be hard to distinguish from’ 36 relapse of depressive symptoms.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [2]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179
RetractedDrugs versus placebo for dysthymia
de Lima, M. S., Moncrieff, J., & Soares, B. G. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001130 · Cited by 82
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
Carter, M. J. (2014) · Therapeutic Recreation Journal · Cited by 15,169
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · cited 1×
“The Geriatric Depression Scale (Yesavage et al., 1982) is the most widely used depression screening scale for older people.”
MethodKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Research works printed but not linked: 61
- Al-Jumah KA, 2012, Patient Prefer Adherence, 6, 87
- 10.1177/026988110001400101 · DOI · Paper page
- Anderson L, 2005, Brit J Gen Pract, 55, 387
- Angst J, 1993, Clin Neuropharmacol, 16, S55
- Ballenger JC, 2001, J Clin Psychiatry, 62, 47
- Barrett JE, 2001, J Fam Pract, 50, 405
- Bedson E, 2014, Health Technol Assess, 18, vii
- Brunoni AR, 2009, Ther Clin Risk Manage, 5, 897
- 10.1002/1520-6394(2001)13:1<38::AID-DA6>3.0.CO;2-7 · DOI
- Chew-Graham A, 2007, Br J General Pract, 57, 364
- Clayton AH, 2003, Int Clin Psychopharmacol, 18, 151
- Cohen J, 1988, Statistical Power Analysis for the Behavioral Sciences, 2nd edn
- Danish University Antidepressant Group, 1986, Psychopharmacol (Berl), 90, 131
- Davidson JRT, 1999, J Clin Psychiatry, 4
- Delgado PL, 2004, J Clin Psychiatry, 65, 16
- Dornseif BE, 1989, Psychopharmacol Bull, 25, 71
- Dubini A, 1997, J Psychopharmacol, 11, S17
- Ekers D, 2007, Psychol Med, 1
- Fava M, 1995, J Clin Psychiatry, 56, 52
- 10.1034/j.1600-0447.2001.00148.x · DOI
- Furukawa TA, 2002, Cochrane Database Syst Rev, 1
- 10.1053/smrv.2002.0235 · doi:10.1053/smrv.2002.0235 · Paper page
- Goldberg D, 1998, Br J Gen Pract, 48, 1840
- Greden JF, 1993, J Clin Psychiatry, 54, 39
- Hannaford PC, 1996, Br J Gen Pract, 46, 333
- Hardy M, Coulter I, Morton C, et al. (2001) Agency for Healthcare Research and Quality (US Department of Health and Human Services); S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Reports/Technology Assessments, No. 64. Available at: http://www.ncbi.nlm.nih.gov/books/NBK36942/ (accessed 10 February 2015).
- Healy D, 1997, J Psychopharmacol, 11, S25
- Heun R, 2012, CINP Vancouver 2012
- Hoffman L, 2003, Am J Manag Care, 9, 70
- Joint Formulary Committee, 2014, British National Formulary
- 10.1046/j.1440-1614.2002.01026.x · doi:10.1046/j.1440-1614.2002.01026.x
- Katon W, 1997, J Clin Psychiatry, 58, 20
- Kennedy SH, 2006, J Psychiatry Neurosci, 31, 122
- Khan A, 1991, Neuropsychopharmacology, 4, 125
- Lader M, 1983, J Clin Psychiatry, 44, 20
- Montejo AL, 2001, J Clin Psychiatry, 62, 10
- Morgan O, 2004, Health Stat Q, 23, 18
- Nihalani ND, 2007, Curr Opin Investig Drugs, 8, 563
- Ottevanger EA, 1991, Br J Clin Res, 2, 125
- Piet J, 2011, CliniPsychol Rev, 31, 1032
- Reimherr FW, 2001, J Clin Psychiatry, 16
- Revicki DA, 1998, J Fam Pract, 47, 446
- Richards A, 2003, Br J Gen Pract, 53, 764
- Robinson DS, 1991, Psychopharmacol Bull, 27, 31
- Robinson P, 1997, J Fam Pract, 44, 562
- Rouillon F, 1991, J Clin Psychiatry, 52, 423
- Royal College of Psychiatrists, 2000, Council Report CR89
- 10.1016/j.biopsych.2005.05.025 · DOI · Paper page
- 10.1037/0022-006X.67.6.837 · DOI · Paper page
- Shepherd DJ, 2009, The Psychiatrist, 33, 41
- 10.1002/(SICI)1099-1077(199709/10)12:5<509::AID-HUP915>3.0.CO;2-1 · doi:10.1002/(sici)1099-1077(199709/10)12:5<509::aid-hup915>3.0.co;2-1
- Thase ME, 1997, J Clin Psychiatry, 158, 23
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Trivedi M, 2012, J Assoc Physicians India, 60, 28
- Tylee A, 1995, Br J Gen Pract, 45, 575
- Waite J, 2013, The ECT Handbook
- Walters G, 1999, J Clin Psychiatry, 60, 21
- Watson S, 2014, J Psychopharmacol, 28, A38
- Wilkinson MJ, 1988, J R Coll Gen Pract, 38, 311
- Wise T, 2014, Neuropsychiatr Dis Treat, 10, 1
- World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders - Clinical Descriptions and Diagnostic Guidelines
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Self-citationExercise as a treatment for depression: a meta-analysis adjusting for publication bias
Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.02.023 · Cited by 1,529
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“Discontinuation of an antidepressant should follow recommendations in related BAP guidelines and taper over 4 weeks if possible (Cleare et al., 2015).”
Self-citationMajor depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Jenkins, T., Nguyen, J., Polglaze, K., & Bertrand, P. (2016) · Nutrients · doi:10.3390/nu8010056 · Cited by 904
“The major therapeutic agents for treating depression are antidepressants, mostly selective serotonin reuptake inhibitors or combined serotonin/noradrenaline reuptake inhibitors [16].”
Background
Metadata
- Authors
- Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., Haddad, P., Katona, C., Lewis, G., Malizia, A., McAllister-Williams, R., Ramchandani, P., Scott, J., Taylor, D., Uher, R., & Meeting, T. M. O. T. C.
- Affiliations
- King's College London (GB)
- Professor of Biological Psychiatry, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, London, UK
- Professor of Psychiatry and Chair of Mood Disorders, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, London, UK
- Professor and Honorary Consultant Psychiatrist, University of Manchester Department of Psychiatry, University of Manchester, Manchester, UK
- Ninewells Hospital (GB)
- Professor of Psychopharmacology, Psychopharmacology Research Unit, Neurosciences Building, University Department of Psychiatry, Warneford Hospital, Oxford, UK
- University of Exeter (GB)
- Professor of Psychiatry, Honorary Consultant Psychiatrist, School of Neurology, Neurobiology & Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, UK
- Warneford Hospital (GB)
- University of York (GB)
- Consultant Psychiatrist, Cromwell House, Greater Manchester West Mental Health NHS Foundation Trust, Salford, UK
- University College London (GB)
- North Bristol NHS Trust (GB)
- Reader in Clinical Psychopharmacology, Institute of Neuroscience, Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne, UK
- Centre for Mental Health (GB)
- Newcastle University (GB)
- Dalhousie University (CA)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-05
- Volume
- 29
- Issue
- 5
- Pages
- 459-525
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2155959499
- Cited by
- 759
- References
- 750
- Citations by year
- 2026: 39 · 2025: 73 · 2024: 71 · 2023: 54 · 2022: 92 · 2021: 110 · 2020: 71 · 2019: 76 · 2018: 60 · 2017: 48 · 2016: 47 · 2015: 12
- FWCI
- 40.11
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depressive disorders, antidepressants, depression treatment, evidence-based clinical guidelines, relapse prevention, relapse treatment, treatment discontinuation, augmentation strategies, antidepressant side effects, adolescent depression
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Depressive Disorder, Humans, Evidence-Based Medicine, Consensus, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. https://app.cochat.ai/papers/10.1177/0269881115581093
- The paper
- Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., Haddad, P., Katona, C., Lewis, G., Malizia, A., McAllister-Williams, R., Ramchandani, P., Scott, J., Taylor, D., Uher, R., & Meeting, T. M. O. T. C. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. https://doi.org/10.1177/0269881115581093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.